BioCardia Inc logo

BCDA - BioCardia Inc News Story

$4.2 0.2  4.7%

Last Trade - 13/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £47.7m
Enterprise Value £32.1m
Revenue £106k
Position in Universe 5462nd / 6841

Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors

Mon 11th January, 2021 1:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210111:nGNX2tgH4Y&default-theme=true


SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.
(https://www.globenewswire.com/Tracker?data=s0L4B4cpS3tWnuZl-Smk_i3-47LfI2jh1YHrg_e9rLG7bqvUBPIWJ3sYgBzNe-BKFmh-l9wsMmHe8l40WK01Uw==) [Nasdaq:
BCDA] a leader in the development of comprehensive solutions for
cardiovascular regenerative therapies, welcomes Krisztina Zsebo, Ph.D., a
31-year veteran of the biotech industry, to its Board of Directors following
her election at BioCardia’s 2020 Annual Meeting of Stockholders in December
2020.

Dr. Zsebo has extensive biotechnology experience in discovery, development,
and commercialization, having raised more than $200 million to support
operations and having launched breakthrough technologies and products with
total annual sales exceeding $3.5 billion. She was an integral member of the
Amgen team that first cloned the molecule that would become Neupogen;
identified the molecule and led the Amgen research team that developed
Stemgen; and led Xenotech, a division of Cell Genysis, which developed
Vectibix, a fully human antibody technology for colorectal cancer. In addition
to her leadership and development experience, Dr. Zsebo has contributed to 113
biotechnology publications, has been awarded 34 composition, process and
method patents, and has 26 patents pending. She earned her Ph.D. in
biochemistry from the University of California, Berkeley.

Among her roles on the BioCardia Board of Directors, Dr. Zsebo is expected to
serve as Chair of a Science and Technology Committee, with Simon H. Stertzer,
M.D. She replaces Fernando L. Fernandez, whose term on BioCardia’s Board of
Directors expired at BioCardia’s 2020 Annual Meeting of Stockholders in
December. In addition, Richard C. Pfenniger, Jr. stepped down from
BioCardia’s Board in January 2021.

“Krisztina’s extensive experience in the industry, ranging from
development to operations to commercialization, provides BioCardia with a
significant resource as we continue our product development plans. We look
forward to the benefit of her contributions to the Board and her unique
perspective at this critical juncture,” commented Peter Altman, Ph.D.,
BioCardia’s President and CEO. “We also wish to thank both Fernando and
Richard for their dedication and service to BioCardia’s board and wish them
all the best in their future endeavors.”

About BioCardia®

BioCardia, Inc.
(https://www.globenewswire.com/Tracker?data=s0L4B4cpS3tWnuZl-Smk_vQIbj8N2AUg-MkaCZ-kPPUbRZkvJtpngg3WvjoKImsPP_XhHLtfdeRWN3YdPqJ5jQ==),
headquartered in San Carlos, California, is developing regenerative biologic
therapies to treat cardiovascular and respiratory disease. CardiAMP autologous
and Neurokinin-1 Receptor Positive allogenic cell therapies are the
Company’s biotherapeutic platforms in clinical development. The Company's
products include the Helix Biotherapeutic Delivery System and its steerable
guide and sheath catheter portfolio. BioCardia also partners with other
biotherapeutic companies to provide its Helix system and clinical support for
their programs studying therapies for the treatment of heart failure, chronic
myocardial ischemia, and acute myocardial infarction. For more information,
visit www.BioCardia.com.

Forward Looking Statements:
This press release contains forward-looking statements that are subject to
many risks and uncertainties. Forward-looking statements include statements
regarding our intentions, beliefs, projections, outlook, analyses or current
expectations.

We may use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey the uncertainty of future events or outcomes to identify these
forward-looking statements. These forward-looking statements reflect our view
as of the time such statement is made and are not guarantees of future
performance or developments. Actual results and events may differ materially
from information contained in the forward-looking statements. BioCardia
expressly disclaims any intent or obligation to update these forward-looking
statements, except as required by law.

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@BioCardia.com
(650) 226-0120

MEDIA CONTACT:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 545-6654


(https://www.globenewswire.com/NewsRoom/AttachmentNg/4641bb53-4913-4654-a337-79383a5c7ab9)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.